EXELExelixisRunning, no new patients
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.5
3 insiders sold shares within a month
Since May 26, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 855 (final count)
- Started
- Jun 25, 2019
- Main results expected
- Jan 31, 2022
- Fully finished
- Jan 31, 2027
- Results posted
- Sep 10, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)
Measured over: Up to 32 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.5, since 2026-05-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03937219 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC